Importantly, a phase 2a trial involving an implantable ultrasound device (Sonocloud‐9) with concomitant balstilimab (anti‐CTLA‐4 antibody), botensilimab (anti‐PD‐1 antibody), and liposomal doxorubicin is actively ongoing for newly diagnosed GBM patients (NCT05864534). The gene discussed is PDCD1; the disease is glioblastoma.